Eisenmenger Complex Management Market
Market Insights on Eisenmenger Complex Management covering sales outlook, demand forecast & up-to-date key trends
Eisenmenger Complex Management Market by Drug Type, Diagnosis, Distribution Channel, End User & Region | Forecast 2023 to 2033
Eisenmenger Complex Management Market Snapshot (2023 to 2033)
The global Eisenmenger complex management market is expected to surpass an impressive valuation of US$ 7.7 Billion in 2023 and is projected to reach US$ 12.9 Billion by 2033, trailing at a CAGR of 5.3%
The increase in the number of patients suffering from mild congenital heart diseases and the growing focus on research and development activities related to the development of advanced drugs are factors anticipated to drive the growth of the global Eisenmenger syndrome treatment market. About 1 in 4 babies with congenital heart diseases have critical CHDs. Infants with the critical disease generally need surgery or other procedures in their first year of life.
Rising investment by major players for the development of innovative solutions and high spending on healthcare infrastructure development are factors anticipated to create new prospects for players operating in the Eisenmenger syndrome treatment market over the forecast period. In addition, growing partnership and agreements between players in order to improve the business presence is expected to support the revenue growth of the target market.
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 7.7Billion |
|
Anticipated Forecast Value (2033) |
US$ 12.9 Billion |
|
Projected Growth Rate (2023 to 2033) |
CAGR 5.3% |
Let us know your requirement to get
100% FREE customization
2018 to 2022 Eisenmenger Complex Management Demand Analysis vs. Forecast 2023 to 2033
The market for Eisenmenger complex treatment market was worth US$ 6.2 Billion in 2018, growing at a CAGR of 4.52% during the historical period. Continuous requirement of medication supports the growth of the Eisenmenger Syndrome Treatment Market.
Eisenmenger Syndrome is a chronic disease and requires medication to be taken for a long period of time. The incidence and prevalence of Eisenmenger syndrome have not been properly defined due to the highly specific nature of the condition. However, according to National Center for Biotechnology Information (NCBI), 2010, an estimated 8% of patients with congenital heart disease are expected to develop Eisenmenger syndrome. Though technological and healthcare advancements have made it possible to correct congenital heart defects, the responses have been poor in the case of patients suffering from Eisenmenger syndrome.
Also, the presence of disease-targeting therapies such as Sildenafil and Bosentan is expected to boost market growth during the forecast period, due to the unavailability of alternative options. Furthermore, combination therapies are also expected to boost market growth over the forecast period. After a comprehensive analysis of the above-mentioned growth factors, the market for Eisenmenger syndrome treatment is projected to grow at a 5.3% CAGR while reaching a market valuation of USD 12.9 billion by end of the forecast period.
Which are Some Prominent Drivers of the Eisenmenger Complex Management Market?
Increasing clinical trials for product development to drive market growth
Major players are investing highly in developing products such as blood thinning agents and endothelin receptor antagonists in order to treat the problems. Increasing clinical trials related to the development of new products is expected to augment the growth of the target market. In 2021, The USA. Food and Drug Administration approved “Pradaxa” a blood thinning agent. The approval of Pradaxa is expected to help pediatric patients have another therapeutic option to treat and prevent potentially deadly blood clots.
The presence of disease-targeting therapies such as Sildenafil and Bosentan has boosted the market growth over the past years and the trend is expected to remain the same, owing to the unavailability of alternative options. Moreover, combination therapies are also expected to boost the growth of the market over the forecast period. European Society of Cardiology Consensus Guidelines, 2015, suggests the use of combination therapy (Sildenafil + Bosentan, and others) in the management of pulmonary hypertension. These factors are expected to boost the growth of the market over the forecast period.
The government of developed and developing countries is spending high on the development of the healthcare sector. Their approach towards providing advanced care to patients along with better diagnostic facilities is gaining traction. Diagnosis tests such as blood tests, electrocardiograms (ECG), and chest X-rays are gaining attraction among consumers. Awareness related to these testing is increasing and is widely adopted by consumers.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Challenges Projected to be Faced by the Market?
High costs of equipment and dearth of infrastructure restraining growth
Factors such as a lack of developed infrastructure and complex regulations by the government for product approval are anticipated to restrain the growth of the global Eisenmenger syndrome treatment market. In addition, the high cost associated with the development of equipment is expected to challenge the growth of this market.
Region-Wise Insights
What is the growth outlook in North America?
North America dominates the market with a significant market share
The market in North America is expected to account for 48.7% market share with a CAGR of 5.1% during the forecast period. The growth is attributable to a high patient pool suffering from chronic diseases. The presence of many players operating in the country and introducing new solutions are factors expected to augment the regional market growth. In addition, increasing acquisition activities by major players in order to enhance the business and enhance the customer base is expected to support the growth of the Eisenmenger syndrome treatment market.
What are the growth prospects in South Asia?
South Asia will propel growth by witnessing the fastest CAGR
The market in South Asia is expected to witness the fastest compound annual growth rate of 5.5 % during the forecast period. Factors responsible for growth in this region are increasing government spending on the healthcare sector, favorable business policies by the government, and the emergence of small and mid-size players with enhanced solutions. These factors are expected to support the growth of Eisenmenger's complex management market.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category wise Insights
By drug type, which segment will possess the maximum share?
Endothelin receptor antagonist to account for the dominant share
This segment is anticipated to dominate the market while capturing a 48.1% segment share in 2023. It is estimated to reflect a CAGR of 6.1% during the forecast period. The growth is attributed to favorable long-term and short-term outcomes in trials with orally active dual endothelin receptor antagonist bosentan in patients with Eisenmenger's syndrome. Furthermore, the safety and efficacy of these drugs in correcting the Eisenmenger syndrome are also driving the growth of this segment. Furthermore, increasing adoption of Endothelin receptor antagonist as a targeted therapy to dilate blood vessels, delay the progression of pulmonary arterial hypertension, and reverse the damage to the lungs and heart are set to fuel this segment over the forthcoming years.
Which is the leading distribution channel in Eisenmenger complex management market?
Hospital pharmacies rule the market with the maximum share
In terms of distribution channels, the hospital pharmacies segment is projected to remain at the forefront in the assessment period. It is estimated to account for a market share of 65% by end of the forecast period. The growth is attributable to the increasing patient visits to hospitals for the treatment of Eisenmenger syndrome.
In addition, the increasing sales of prescribed drugs for the treatment of this disorder from hospital pharmacies are anticipated to support the growth of this segment. Besides, many government agencies are likely to set up awareness campaigns in hospitals to educate the general public about this condition and the drugs available for treatment. This factor is also expected to boost the growth of this segment in the near future.
Start-ups in Eisenmenger Complex Management Market
- Founded in 2015, Morphogen-IX is a Cambridge, United Kingdom-based start-up that is developing a new treatment for pulmonary arterial hypertension (PAH). Its leading candidate can directly target the major pathway implicated in human genetic studies (BMP9 and BMP10) which are small molecule-based receptors. This company was granted funding of USD 25.3 million from Medicxi, Cambridge Innovation Capital, Index Ventures, Cambridge Enterprise, and 2 others. The latest funding round was held in December 2018.
- Founded in 2012, ‘1 Drop diagnostics’ is a Neuchatel, Switzerland-based start-up that provides finger-prick point-of-care diagnostic solutions. The proprietary technology uses a combination of lab-on-chip microfluidic technology that enables biomarker testing to occur using very small volumes of blood, and advanced photonics to easily detect fluorescence due to the immunoassays. The first application is cardiovascular health, using biomarkers such as NT-proBNP, D-Dimer, Troponin, and C-reactive protein. It was granted funding of USD 8 million from Christian Wildmoser, Hans-Peter Strebel, Beat Schillig, and 9 Other Investors.
Market Competition
The global Eisenmenger syndrome treatment market is highly competitive due to the presence of a large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. The major players in the market are Actelion Pharmaceuticals Ltd, Gilead Sciences, Inc., Pfizer, Inc, Teva Pharmaceutical Industries Ltd, AstraZeneca plc., Novartis AG, Merck and Co., Inc., GlaxoSmithKline plc., Mylan N.V, Bayer AG.
Some recent developments in this industry are:
- In July 2022, Cereno Scientific announced that the first patient had been enrolled in the Phase II study in pulmonary arterial hypertension (PAH) with drug candidate CS1.
- In June 2022, Gossamer Bio, Inc. declared the publication of key preclinical data supporting the potential of seralutinib for the treatment of pulmonary arterial hypertension (PAH).
- In December 2021, Aerovate Therapeutics, a clinical-stage biopharmaceutical company based in the United States, started the Phase 2b/3 clinical trial for testing imatinib, its experimental inhaled formulation in people with Eisenmenger syndrome. The trial is set to help the company in achieving the goal of enhancing the lives of patients suffering from rare cardiovascular diseases. This test will evaluate the ability of AV-101 to resist blood flow in the blood vessels of the lungs.
- In December 2021, Alembic Pharmaceuticals, a multinational pharmaceutical company headquartered in India, bagged approval from the United States Food and Drug Administration (USFDA) for the marketing of Selexipag December 2021, Alembic Pharmaceuticals tablets. These can now be used to treat pulmonary arterial hypertension. The company’s new drug is considered to be the generic equivalent to Uptravi, the Reference Listed Drug (RLD).
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 7.7 Billion |
|
Market Value in 2033 |
US$ 12.9 Billion |
|
Growth Rate |
CAGR of 5.3% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in USD billion and CAGR from 2023 to 2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Eisenmenger Complex Management Industry Survey
By Drug Type:
- Antiarrhythmic Agents
- Blood Thinning Agents
- Endothelin Receptor Antagonist
- Others
By Diagnosis:
- Blood tests
- Electrocardiogram
- Chest X-ray
- Echocardiogram
- CT Scan
- MRI
- Cardiac Catheterization
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By End User:
- Hospitals & Clinics
- Laboratories
- Others
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa (MEA)
Frequently Asked Questions
What is the anticipated growth of the Eisenmenger Complex Management Market until 2033?
FMI projects the global Eisenmenger Complex Management Market to expand at a 5.3 % value CAGR by 2033.
What is the estimated market value of the Eisenmenger Complex Management Market expected in 2033?
The global Eisenmenger Complex Management Market is expected to garner a market value of US$ 12.9 billion by 2033.
Which region is forecast to be the most lucrative for Eisenmenger Complex Management Market growth?
FMI has projected North America to be one of the most profitable regions for the Eisenmenger Complex Management Market.
Which region is expected to grow fastest during the forecast period?
South Asia region is expected to grow fastest during the forecast period.
Table of Content
1. Executive Summary | Eisenmenger Complex Management Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033 5.3.1. Antiarrhythmic Agents 5.3.2. Blood Thinning Agents 5.3.3. Endothelin Receptor Antagonist 5.3.4. Others 5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033 6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis, 2023 to 2033 6.3.1. Blood tests 6.3.2. Electrocardiogram 6.3.3. Chest X-ray 6.3.4. Echocardiogram 6.3.5. CT Scan 6.3.6. MRI 6.3.7. Cardiac Catheterization 6.4. Y-o-Y Growth Trend Analysis By Diagnosis, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Diagnosis, 2023 to 2033 7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 7.3.1. Hospital Pharmacies 7.3.2. Online Pharmacies 7.3.3. Retail Pharmacies 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-user 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By End-user, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-user, 2023 to 2033 8.3.1. Hospitals & Clinics 8.3.2. Laboratories 8.3.3. Others 8.4. Y-o-Y Growth Trend Analysis By End-user, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By End-user, 2023 to 2033 9. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 9.3.1. North America 9.3.2. Latin America 9.3.3. Europe 9.3.4. South Asia 9.3.5. East Asia 9.3.6. Oceania 9.3.7. Middle East & Africa (MEA) 9.4. Market Attractiveness Analysis By Region 10. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. USA 10.2.1.2. Canada 10.2.2. By Drug Type 10.2.3. By Diagnosis 10.2.4. By Distribution Channel 10.2.5. By End-user 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Type 10.3.3. By Diagnosis 10.3.4. By Distribution Channel 10.3.5. By End-user 10.4. Key Takeaways 11. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Drug Type 11.2.3. By Diagnosis 11.2.4. By Distribution Channel 11.2.5. By End-user 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Type 11.3.3. By Diagnosis 11.3.4. By Distribution Channel 11.3.5. By End-user 11.4. Key Takeaways 12. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. UK 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Europe 12.2.2. By Drug Type 12.2.3. By Diagnosis 12.2.4. By Distribution Channel 12.2.5. By End-user 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Type 12.3.3. By Diagnosis 12.3.4. By Distribution Channel 12.3.5. By End-user 12.4. Key Takeaways 13. South Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Malaysia 13.2.1.3. Singapore 13.2.1.4. Thailand 13.2.1.5. Rest of South Asia 13.2.2. By Drug Type 13.2.3. By Diagnosis 13.2.4. By Distribution Channel 13.2.5. By End-user 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Type 13.3.3. By Diagnosis 13.3.4. By Distribution Channel 13.3.5. By End-user 13.4. Key Takeaways 14. East Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Drug Type 14.2.3. By Diagnosis 14.2.4. By Distribution Channel 14.2.5. By End-user 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Type 14.3.3. By Diagnosis 14.3.4. By Distribution Channel 14.3.5. By End-user 14.4. Key Takeaways 15. Oceania Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. Australia 15.2.1.2. New Zealand 15.2.2. By Drug Type 15.2.3. By Diagnosis 15.2.4. By Distribution Channel 15.2.5. By End-user 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Type 15.3.3. By Diagnosis 15.3.4. By Distribution Channel 15.3.5. By End-user 15.4. Key Takeaways 16. Middle East & Africa Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. GCC Countries 16.2.1.2. South Africa 16.2.1.3. Israel 16.2.1.4. Rest of Middle East & Africa 16.2.2. By Drug Type 16.2.3. By Diagnosis 16.2.4. By Distribution Channel 16.2.5. By End-user 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Drug Type 16.3.3. By Diagnosis 16.3.4. By Distribution Channel 16.3.5. By End-user 16.4. Key Takeaways 17. Key Countries Analysis 17.1. USA 17.1.1. Pricing Analysis 17.1.2. Market Share Analysis, 2022 17.1.2.1. By Drug Type 17.1.2.2. By Diagnosis 17.1.2.3. By Distribution Channel 17.1.2.4. By End-user 17.2. Canada 17.2.1. Pricing Analysis 17.2.2. Market Share Analysis, 2022 17.2.2.1. By Drug Type 17.2.2.2. By Diagnosis 17.2.2.3. By Distribution Channel 17.2.2.4. By End-user 17.3. Brazil 17.3.1. Pricing Analysis 17.3.2. Market Share Analysis, 2022 17.3.2.1. By Drug Type 17.3.2.2. By Diagnosis 17.3.2.3. By Distribution Channel 17.3.2.4. By End-user 17.4. Mexico 17.4.1. Pricing Analysis 17.4.2. Market Share Analysis, 2022 17.4.2.1. By Drug Type 17.4.2.2. By Diagnosis 17.4.2.3. By Distribution Channel 17.4.2.4. By End-user 17.5. Germany 17.5.1. Pricing Analysis 17.5.2. Market Share Analysis, 2022 17.5.2.1. By Drug Type 17.5.2.2. By Diagnosis 17.5.2.3. By Distribution Channel 17.5.2.4. By End-user 17.6. UK 17.6.1. Pricing Analysis 17.6.2. Market Share Analysis, 2022 17.6.2.1. By Drug Type 17.6.2.2. By Diagnosis 17.6.2.3. By Distribution Channel 17.6.2.4. By End-user 17.7. France 17.7.1. Pricing Analysis 17.7.2. Market Share Analysis, 2022 17.7.2.1. By Drug Type 17.7.2.2. By Diagnosis 17.7.2.3. By Distribution Channel 17.7.2.4. By End-user 17.8. Spain 17.8.1. Pricing Analysis 17.8.2. Market Share Analysis, 2022 17.8.2.1. By Drug Type 17.8.2.2. By Diagnosis 17.8.2.3. By Distribution Channel 17.8.2.4. By End-user 17.9. Italy 17.9.1. Pricing Analysis 17.9.2. Market Share Analysis, 2022 17.9.2.1. By Drug Type 17.9.2.2. By Diagnosis 17.9.2.3. By Distribution Channel 17.9.2.4. By End-user 17.10. India 17.10.1. Pricing Analysis 17.10.2. Market Share Analysis, 2022 17.10.2.1. By Drug Type 17.10.2.2. By Diagnosis 17.10.2.3. By Distribution Channel 17.10.2.4. By End-user 17.11. Malaysia 17.11.1. Pricing Analysis 17.11.2. Market Share Analysis, 2022 17.11.2.1. By Drug Type 17.11.2.2. By Diagnosis 17.11.2.3. By Distribution Channel 17.11.2.4. By End-user 17.12. Singapore 17.12.1. Pricing Analysis 17.12.2. Market Share Analysis, 2022 17.12.2.1. By Drug Type 17.12.2.2. By Diagnosis 17.12.2.3. By Distribution Channel 17.12.2.4. By End-user 17.13. Thailand 17.13.1. Pricing Analysis 17.13.2. Market Share Analysis, 2022 17.13.2.1. By Drug Type 17.13.2.2. By Diagnosis 17.13.2.3. By Distribution Channel 17.13.2.4. By End-user 17.14. China 17.14.1. Pricing Analysis 17.14.2. Market Share Analysis, 2022 17.14.2.1. By Drug Type 17.14.2.2. By Diagnosis 17.14.2.3. By Distribution Channel 17.14.2.4. By End-user 17.15. Japan 17.15.1. Pricing Analysis 17.15.2. Market Share Analysis, 2022 17.15.2.1. By Drug Type 17.15.2.2. By Diagnosis 17.15.2.3. By Distribution Channel 17.15.2.4. By End-user 17.16. South Korea 17.16.1. Pricing Analysis 17.16.2. Market Share Analysis, 2022 17.16.2.1. By Drug Type 17.16.2.2. By Diagnosis 17.16.2.3. By Distribution Channel 17.16.2.4. By End-user 17.17. Australia 17.17.1. Pricing Analysis 17.17.2. Market Share Analysis, 2022 17.17.2.1. By Drug Type 17.17.2.2. By Diagnosis 17.17.2.3. By Distribution Channel 17.17.2.4. By End-user 17.18. New Zealand 17.18.1. Pricing Analysis 17.18.2. Market Share Analysis, 2022 17.18.2.1. By Drug Type 17.18.2.2. By Diagnosis 17.18.2.3. By Distribution Channel 17.18.2.4. By End-user 17.19. GCC Countries 17.19.1. Pricing Analysis 17.19.2. Market Share Analysis, 2022 17.19.2.1. By Drug Type 17.19.2.2. By Diagnosis 17.19.2.3. By Distribution Channel 17.19.2.4. By End-user 17.20. South Africa 17.20.1. Pricing Analysis 17.20.2. Market Share Analysis, 2022 17.20.2.1. By Drug Type 17.20.2.2. By Diagnosis 17.20.2.3. By Distribution Channel 17.20.2.4. By End-user 17.21. Israel 17.21.1. Pricing Analysis 17.21.2. Market Share Analysis, 2022 17.21.2.1. By Drug Type 17.21.2.2. By Diagnosis 17.21.2.3. By Distribution Channel 17.21.2.4. By End-user 18. Market Structure Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Market Share Analysis of Top Players 18.3.1. By Regional 18.3.2. By Drug Type 18.3.3. By Diagnosis 18.3.4. By Distribution Channel 18.3.5. By End-user 19. Competition Analysis 19.1. Competition Deep Dive 19.1.1. Actelion Pharmaceuticals Ltd. 19.1.1.1. Overview 19.1.1.2. Product Portfolio 19.1.1.3. Profitability by Market Segments 19.1.1.4. Sales Footprint 19.1.1.5. Strategy Overview 19.1.1.5.1. Marketing Strategy 19.1.2. Gilead Sciences, Inc. 19.1.2.1. Overview 19.1.2.2. Product Portfolio 19.1.2.3. Profitability by Market Segments 19.1.2.4. Sales Footprint 19.1.2.5. Strategy Overview 19.1.2.5.1. Marketing Strategy 19.1.3. Pfizer, Inc. 19.1.3.1. Overview 19.1.3.2. Product Portfolio 19.1.3.3. Profitability by Market Segments 19.1.3.4. Sales Footprint 19.1.3.5. Strategy Overview 19.1.3.5.1. Marketing Strategy 19.1.4. Teva Pharmaceutical Industries Ltd. 19.1.4.1. Overview 19.1.4.2. Product Portfolio 19.1.4.3. Profitability by Market Segments 19.1.4.4. Sales Footprint 19.1.4.5. Strategy Overview 19.1.4.5.1. Marketing Strategy 19.1.5. AstraZeneca plc. 19.1.5.1. Overview 19.1.5.2. Product Portfolio 19.1.5.3. Profitability by Market Segments 19.1.5.4. Sales Footprint 19.1.5.5. Strategy Overview 19.1.5.5.1. Marketing Strategy 19.1.6. Novartis AG 19.1.6.1. Overview 19.1.6.2. Product Portfolio 19.1.6.3. Profitability by Market Segments 19.1.6.4. Sales Footprint 19.1.6.5. Strategy Overview 19.1.6.5.1. Marketing Strategy 19.1.7. Merck and Co., Inc. 19.1.7.1. Overview 19.1.7.2. Product Portfolio 19.1.7.3. Profitability by Market Segments 19.1.7.4. Sales Footprint 19.1.7.5. Strategy Overview 19.1.7.5.1. Marketing Strategy 19.1.8. GlaxoSmithKline plc. 19.1.8.1. Overview 19.1.8.2. Product Portfolio 19.1.8.3. Profitability by Market Segments 19.1.8.4. Sales Footprint 19.1.8.5. Strategy Overview 19.1.8.5.1. Marketing Strategy 19.1.9. Mylan N.V. 19.1.9.1. Overview 19.1.9.2. Product Portfolio 19.1.9.3. Profitability by Market Segments 19.1.9.4. Sales Footprint 19.1.9.5. Strategy Overview 19.1.9.5.1. Marketing Strategy 19.1.10. Bayer AG 19.1.10.1. Overview 19.1.10.2. Product Portfolio 19.1.10.3. Profitability by Market Segments 19.1.10.4. Sales Footprint 19.1.10.5. Strategy Overview 19.1.10.5.1. Marketing Strategy 20. Assumptions & Acronyms Used 21. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 3: Global Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 4: Global Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 5: Global Value (US$ Million) Forecast by End-user, 2018 to 2033 Table 6: North America Value (US$ Million) Forecast by Country, 2018 to 2033 Table 7: North America Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 8: North America Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 9: North America Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 10: North America Value (US$ Million) Forecast by End-user, 2018 to 2033 Table 11: Latin America Value (US$ Million) Forecast by Country, 2018 to 2033 Table 12: Latin America Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 13: Latin America Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 14: Latin America Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 15: Latin America Value (US$ Million) Forecast by End-user, 2018 to 2033 Table 16: Europe Value (US$ Million) Forecast by Country, 2018 to 2033 Table 17: Europe Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 18: Europe Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 19: Europe Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 20: Europe Value (US$ Million) Forecast by End-user, 2018 to 2033 Table 21: South Asia Value (US$ Million) Forecast by Country, 2018 to 2033 Table 22: South Asia Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 23: South Asia Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 24: South Asia Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 25: South Asia Value (US$ Million) Forecast by End-user, 2018 to 2033 Table 26: East Asia Value (US$ Million) Forecast by Country, 2018 to 2033 Table 27: East Asia Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 28: East Asia Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 29: East Asia Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 30: East Asia Value (US$ Million) Forecast by End-user, 2018 to 2033 Table 31: Oceania Value (US$ Million) Forecast by Country, 2018 to 2033 Table 32: Oceania Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 33: Oceania Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 34: Oceania Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 35: Oceania Value (US$ Million) Forecast by End-user, 2018 to 2033 Table 36: Middle East & Africa Value (US$ Million) Forecast by Country, 2018 to 2033 Table 37: Middle East & Africa Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 38: Middle East & Africa Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 39: Middle East & Africa Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 40: Middle East & Africa Value (US$ Million) Forecast by End-user, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Value (US$ Million) by Drug Type, 2023 to 2033 Figure 2: Global Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 3: Global Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 4: Global Value (US$ Million) by End-user, 2023 to 2033 Figure 5: Global Value (US$ Million) by Region, 2023 to 2033 Figure 6: Global Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 7: Global Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 8: Global Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 9: Global Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 10: Global Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 11: Global Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 12: Global Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 13: Global Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 14: Global Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 15: Global Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 16: Global Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 17: Global Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 18: Global Value (US$ Million) Analysis by End-user, 2018 to 2033 Figure 19: Global Value Share (%) and BPS Analysis by End-user, 2023 to 2033 Figure 20: Global Y-o-Y Growth (%) Projections by End-user, 2023 to 2033 Figure 21: Global Attractiveness by Drug Type, 2023 to 2033 Figure 22: Global Attractiveness by Diagnosis, 2023 to 2033 Figure 23: Global Attractiveness by Distribution Channel, 2023 to 2033 Figure 24: Global Attractiveness by End-user, 2023 to 2033 Figure 25: Global Attractiveness by Region, 2023 to 2033 Figure 26: North America Value (US$ Million) by Drug Type, 2023 to 2033 Figure 27: North America Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 28: North America Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 29: North America Value (US$ Million) by End-user, 2023 to 2033 Figure 30: North America Value (US$ Million) by Country, 2023 to 2033 Figure 31: North America Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 32: North America Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 33: North America Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 34: North America Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 35: North America Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 36: North America Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 37: North America Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 38: North America Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 39: North America Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 40: North America Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 41: North America Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 42: North America Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 43: North America Value (US$ Million) Analysis by End-user, 2018 to 2033 Figure 44: North America Value Share (%) and BPS Analysis by End-user, 2023 to 2033 Figure 45: North America Y-o-Y Growth (%) Projections by End-user, 2023 to 2033 Figure 46: North America Attractiveness by Drug Type, 2023 to 2033 Figure 47: North America Attractiveness by Diagnosis, 2023 to 2033 Figure 48: North America Attractiveness by Distribution Channel, 2023 to 2033 Figure 49: North America Attractiveness by End-user, 2023 to 2033 Figure 50: North America Attractiveness by Country, 2023 to 2033 Figure 51: Latin America Value (US$ Million) by Drug Type, 2023 to 2033 Figure 52: Latin America Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 53: Latin America Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 54: Latin America Value (US$ Million) by End-user, 2023 to 2033 Figure 55: Latin America Value (US$ Million) by Country, 2023 to 2033 Figure 56: Latin America Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 57: Latin America Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 58: Latin America Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 59: Latin America Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 60: Latin America Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 61: Latin America Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 62: Latin America Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 63: Latin America Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 64: Latin America Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 65: Latin America Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 66: Latin America Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 67: Latin America Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 68: Latin America Value (US$ Million) Analysis by End-user, 2018 to 2033 Figure 69: Latin America Value Share (%) and BPS Analysis by End-user, 2023 to 2033 Figure 70: Latin America Y-o-Y Growth (%) Projections by End-user, 2023 to 2033 Figure 71: Latin America Attractiveness by Drug Type, 2023 to 2033 Figure 72: Latin America Attractiveness by Diagnosis, 2023 to 2033 Figure 73: Latin America Attractiveness by Distribution Channel, 2023 to 2033 Figure 74: Latin America Attractiveness by End-user, 2023 to 2033 Figure 75: Latin America Attractiveness by Country, 2023 to 2033 Figure 76: Europe Value (US$ Million) by Drug Type, 2023 to 2033 Figure 77: Europe Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 78: Europe Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 79: Europe Value (US$ Million) by End-user, 2023 to 2033 Figure 80: Europe Value (US$ Million) by Country, 2023 to 2033 Figure 81: Europe Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 82: Europe Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 83: Europe Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 84: Europe Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 85: Europe Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 86: Europe Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 87: Europe Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 88: Europe Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 89: Europe Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 90: Europe Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 91: Europe Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 92: Europe Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 93: Europe Value (US$ Million) Analysis by End-user, 2018 to 2033 Figure 94: Europe Value Share (%) and BPS Analysis by End-user, 2023 to 2033 Figure 95: Europe Y-o-Y Growth (%) Projections by End-user, 2023 to 2033 Figure 96: Europe Attractiveness by Drug Type, 2023 to 2033 Figure 97: Europe Attractiveness by Diagnosis, 2023 to 2033 Figure 98: Europe Attractiveness by Distribution Channel, 2023 to 2033 Figure 99: Europe Attractiveness by End-user, 2023 to 2033 Figure 100: Europe Attractiveness by Country, 2023 to 2033 Figure 101: South Asia Value (US$ Million) by Drug Type, 2023 to 2033 Figure 102: South Asia Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 103: South Asia Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 104: South Asia Value (US$ Million) by End-user, 2023 to 2033 Figure 105: South Asia Value (US$ Million) by Country, 2023 to 2033 Figure 106: South Asia Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 107: South Asia Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 108: South Asia Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 109: South Asia Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 110: South Asia Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 111: South Asia Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 112: South Asia Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 113: South Asia Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 114: South Asia Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 115: South Asia Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 116: South Asia Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 117: South Asia Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 118: South Asia Value (US$ Million) Analysis by End-user, 2018 to 2033 Figure 119: South Asia Value Share (%) and BPS Analysis by End-user, 2023 to 2033 Figure 120: South Asia Y-o-Y Growth (%) Projections by End-user, 2023 to 2033 Figure 121: South Asia Attractiveness by Drug Type, 2023 to 2033 Figure 122: South Asia Attractiveness by Diagnosis, 2023 to 2033 Figure 123: South Asia Attractiveness by Distribution Channel, 2023 to 2033 Figure 124: South Asia Attractiveness by End-user, 2023 to 2033 Figure 125: South Asia Attractiveness by Country, 2023 to 2033 Figure 126: East Asia Value (US$ Million) by Drug Type, 2023 to 2033 Figure 127: East Asia Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 128: East Asia Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 129: East Asia Value (US$ Million) by End-user, 2023 to 2033 Figure 130: East Asia Value (US$ Million) by Country, 2023 to 2033 Figure 131: East Asia Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 132: East Asia Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 133: East Asia Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 134: East Asia Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 135: East Asia Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 136: East Asia Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 137: East Asia Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 138: East Asia Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 139: East Asia Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 140: East Asia Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 141: East Asia Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 142: East Asia Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 143: East Asia Value (US$ Million) Analysis by End-user, 2018 to 2033 Figure 144: East Asia Value Share (%) and BPS Analysis by End-user, 2023 to 2033 Figure 145: East Asia Y-o-Y Growth (%) Projections by End-user, 2023 to 2033 Figure 146: East Asia Attractiveness by Drug Type, 2023 to 2033 Figure 147: East Asia Attractiveness by Diagnosis, 2023 to 2033 Figure 148: East Asia Attractiveness by Distribution Channel, 2023 to 2033 Figure 149: East Asia Attractiveness by End-user, 2023 to 2033 Figure 150: East Asia Attractiveness by Country, 2023 to 2033 Figure 151: Oceania Value (US$ Million) by Drug Type, 2023 to 2033 Figure 152: Oceania Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 153: Oceania Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 154: Oceania Value (US$ Million) by End-user, 2023 to 2033 Figure 155: Oceania Value (US$ Million) by Country, 2023 to 2033 Figure 156: Oceania Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 157: Oceania Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 158: Oceania Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 159: Oceania Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 160: Oceania Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 161: Oceania Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 162: Oceania Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 163: Oceania Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 164: Oceania Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 165: Oceania Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 166: Oceania Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 167: Oceania Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 168: Oceania Value (US$ Million) Analysis by End-user, 2018 to 2033 Figure 169: Oceania Value Share (%) and BPS Analysis by End-user, 2023 to 2033 Figure 170: Oceania Y-o-Y Growth (%) Projections by End-user, 2023 to 2033 Figure 171: Oceania Attractiveness by Drug Type, 2023 to 2033 Figure 172: Oceania Attractiveness by Diagnosis, 2023 to 2033 Figure 173: Oceania Attractiveness by Distribution Channel, 2023 to 2033 Figure 174: Oceania Attractiveness by End-user, 2023 to 2033 Figure 175: Oceania Attractiveness by Country, 2023 to 2033 Figure 176: Middle East & Africa Value (US$ Million) by Drug Type, 2023 to 2033 Figure 177: Middle East & Africa Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 178: Middle East & Africa Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 179: Middle East & Africa Value (US$ Million) by End-user, 2023 to 2033 Figure 180: Middle East & Africa Value (US$ Million) by Country, 2023 to 2033 Figure 181: Middle East & Africa Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 182: Middle East & Africa Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 183: Middle East & Africa Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 184: Middle East & Africa Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 185: Middle East & Africa Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 186: Middle East & Africa Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 187: Middle East & Africa Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 188: Middle East & Africa Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 189: Middle East & Africa Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 190: Middle East & Africa Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 191: Middle East & Africa Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 192: Middle East & Africa Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 193: Middle East & Africa Value (US$ Million) Analysis by End-user, 2018 to 2033 Figure 194: Middle East & Africa Value Share (%) and BPS Analysis by End-user, 2023 to 2033 Figure 195: Middle East & Africa Y-o-Y Growth (%) Projections by End-user, 2023 to 2033 Figure 196: Middle East & Africa Attractiveness by Drug Type, 2023 to 2033 Figure 197: Middle East & Africa Attractiveness by Diagnosis, 2023 to 2033 Figure 198: Middle East & Africa Attractiveness by Distribution Channel, 2023 to 2033 Figure 199: Middle East & Africa Attractiveness by End-user, 2023 to 2033 Figure 200: Middle East & Africa Attractiveness by Country, 2023 to 2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
